Published in Eur J Nucl Med Mol Imaging on May 30, 2012
Reply to comment on Pepe et al.: Somatostatin receptor SPECT. Eur J Nucl Med Mol Imaging (2012) 0.75
99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med (2000) 1.83
Radiopharmaceutical development of radiolabelled peptides. Eur J Nucl Med Mol Imaging (2012) 1.34
An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med (2003) 1.18
99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging (2006) 1.13
99mTc-N4-[Tyr3]Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3]Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy. Cancer Biother Radiopharm (2004) 0.93
99mTc-EDDA/HYNIC-TOC somatostatin receptor scintigraphy in daily clinical practice. Med Sci Monit (2010) 0.92
Somatostatin receptor SPECT. Eur J Nucl Med Mol Imaging (2012) 0.91
Radio-guided surgery with the use of [99mTc-EDDA/HYNIC]octreotate in intra-operative detection of neuroendocrine tumours of the gastrointestinal tract. Eur J Nucl Med Mol Imaging (2007) 0.91
Technetium-99m-sestamibi subtraction scintigraphy vs. ultrasonography combined with a rapid parathyroid hormone assay in parathyroid aspirates in preoperative localization of parathyroid adenomas and in directing surgical approach. Clin Endocrinol (Oxf) (2006) 2.30
Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging (2011) 2.08
Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center. Pol Arch Med Wewn (2015) 1.57
Factors connected with the female sex seem to play an important role in differentiated thyroid cancer. Gynecol Endocrinol (2011) 1.41
Evaluation of Halle, Miami, Rome, and Vienna intraoperative iPTH assay criteria in guiding minimally invasive parathyroidectomy. Langenbecks Arch Surg (2009) 1.21
Intraoperative parathyroid hormone assay improves outcomes of minimally invasive parathyroidectomy mainly in patients with a presumed solitary parathyroid adenoma and missing concordance of preoperative imaging. Clin Endocrinol (Oxf) (2007) 1.11
Five-year follow-up of a randomized clinical trial of total thyroidectomy versus Dunhill operation versus bilateral subtotal thyroidectomy for multinodular nontoxic goiter. World J Surg (2010) 1.10
Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. Eur J Nucl Med Mol Imaging (2012) 1.10
Treatment and screening of hypothyroidism in pregnancy: results of a European survey. Eur J Endocrinol (2011) 1.00
Clinical value of intraoperative neuromonitoring of the recurrent laryngeal nerves in improving outcomes of surgery for well-differentiated thyroid cancer. Pol Przegl Chir (2011) 0.98
Reference values for thyroid volume established by ultrasound in Polish schoolchildren. Endokrynol Pol (2012) 0.94
Iodine-deficiency prophylaxis and the restriction of salt consumption - a 21st century challenge. Endokrynol Pol (2010) 0.92
The prevalence of benign and malignant neoplasms in acromegalic patients. Endokrynol Pol (2010) 0.91
Efficacy and complications of neurosurgical treatment of acromegaly. Pituitary (2011) 0.90
[A case of Graves-Basedow disease with orbitopathy and papillary thyroid cancer]. Endokrynol Pol (2009) 0.86
Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET. Radiother Oncol (2011) 0.86
Iodine prophylaxis--the protective factor against stomach cancer in iodine deficient areas. Eur J Nutr (2007) 0.85
An assessment of the effectiveness of iodine prophylaxis in pregnant women - analysis in one of reference gynaecological-obstetric centres in Poland. Endokrynol Pol (2015) 0.84
Neuroendocrine tumours of rare location. Endokrynol Pol (2010) 0.83
Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging (2011) 0.82
Diagnostics and Treatment of Thyroid Carcinoma. Endokrynol Pol (2016) 0.82
Adenomatoid tumour of the adrenal gland: a case report and literature review. Pol J Pathol (2010) 0.82
Identification of inflamed atherosclerotic plaque using 123 I-labeled interleukin-2 scintigraphy in high-risk peritoneal dialysis patients: a pilot study. Perit Dial Int (2009) 0.81
Factors connected with the female sex seem to play an important role in differentiated thyroid cancer. Gynecol Endocrinol (2011) 0.81
Evaluation of gastric emptying in familial and sporadic Parkinson disease. Parkinsonism Relat Disord (2009) 0.80
[Withdrawal syndrome complicated with heart left ventricle dysfunction in young woman addicted to alcohol]. Przegl Lek (2007) 0.80
Gastroduodenal neuroendocrine neoplasms including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol (2013) 0.80
[Protein losing enteropathy (PLE) detected by Tc99m-labelled human serum albumin abdominal scintigraphy--case report]. Przegl Lek (2003) 0.80
Hypothyroidism during treatment with tyrosine kinase inhibitors. Endokrynol Pol (2012) 0.79
Five-year follow-up of a randomized clinical trial of unilateral thyroid lobectomy with or without postoperative levothyroxine treatment. World J Surg (2010) 0.79
The predictive value of the IGF-1 level in acromegaly patients treated by surgery and a somatostatin analogue. Endokrynol Pol (2011) 0.78
Recommendations of the Polish Society of Endocrinology and Polish Diabetes Association for the management of thyroid dysfunction in type 1 and type 2 diabetes. Endokrynol Pol (2013) 0.78
Imaging of inflamed carotid artery atherosclerotic plaques with the use of 99mTc-HYNIC-IL-2 scintigraphy in end-stage renal disease patients. Eur J Nucl Med Mol Imaging (2012) 0.78
Use of Tc99m-nanocolloid for sentinel nodes identification in cervical cancer. Nucl Med Rev Cent East Eur (2003) 0.78
[The incidence of neoplasm in women using contraceptives]. Przegl Lek (2010) 0.77
Positive family history of thyroid disease as a risk factor for differentiated thyroid carcinoma. Pol Arch Med Wewn (2011) 0.77
Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours. Endokrynol Pol (2011) 0.77
Thyroid disorders-assessments of trace elements, clinical, and laboratory parameters. Biol Trace Elem Res (2010) 0.77
Amiodarone and the thyroid. Endokrynol Pol (2015) 0.77
Dietary patterns as risk factors of differentiated thyroid carcinoma. Postepy Hig Med Dosw (Online) (2012) 0.77
Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours? Nucl Med Rev Cent East Eur (2011) 0.77
Adrenal incidentaloma in adults - management recommendations by the Polish Society of Endocrinology. Endokrynol Pol (2016) 0.77
Acromegaly--a novel view of the patient. Polish proposals for diagnostic and therapeutic procedures in the light of recent reports. Endokrynol Pol (2014) 0.77
Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors? Clin Imaging (2012) 0.76
Utility of intraoperative bilateral internal jugular venous sampling with rapid parathyroid hormone testing in guiding patients with a negative sestamibi scan for minimally invasive parathyroidectomy--a randomized controlled trial. Langenbecks Arch Surg (2009) 0.76
Nephrotoxicity after PRRT - still a serious clinical problem? Renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATATE and 90Y/177Lu-DOTATATE. Endokrynol Pol (2013) 0.76
[Management of Graves' orbitopathy. Comments on the EUGOGO consensus statement]. Endokrynol Pol (2009) 0.76
Polish Society of Endocrinology Position statement on endocrine disrupting chemicals (EDCs). Endokrynol Pol (2015) 0.76
[Somatostatin receptors expression (SSTR1-SSTR5) in pheochromocytomas]. Przegl Lek (2008) 0.76
[Assessment of 25(OH)D3, concentration levels in patients with papillary thyroid cancer compared to patients with Hashimoto's thyroiditis]. Przegl Lek (2013) 0.76
Polish experience in Peptide receptor radionuclide therapy. Recent Results Cancer Res (2013) 0.75
PRRT as neoadjuvant treatment in NET. Recent Results Cancer Res (2013) 0.75
Comment on long-term risk in radioiodine treatment of hyperthyroidism. Eur J Nucl Med Mol Imaging (2008) 0.75
Expression of cyclooxygenase-2 (COX-2) in pituitary tumours. Med Sci Monit (2012) 0.75
[Acute suicidal carbofuran poisoning--case report]. Przegl Lek (2007) 0.75
Macro- and microadenoma of thyrotropin secreting pituitary tumors--two clinical cases. Przegl Lek (2003) 0.75
NEN - the role of somatostatin receptor scintigraphy in clinical setting. Nucl Med Rev Cent East Eur (2016) 0.75
New forms of radionuclide therapy with (90)Y in oncology. Nucl Med Rev Cent East Eur (2008) 0.75
Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol (2017) 0.75
Pancreatic neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol (2017) 0.75
Noninsulinoma pancreatogenous hypoglycaemia in adults--a spotlight on its genetics. Endokrynol Pol (2015) 0.75
Biokinetics of ¹³¹I after endogenous and exogenous stimulation of TSH in patients with DTC. Nucl Med Rev Cent East Eur (2010) 0.75
Optimization of image reconstruction method for SPECT studies performed using [⁹⁹mTc-EDDA/HYNIC] octreotate in patients with neuroendocrine tumors. Nucl Med Rev Cent East Eur (2013) 0.75
[Evaluation of regional cerebral blood flow using 99mTc-ECD SPECT in ethanol dependent patients: pilot study]. Przegl Lek (2007) 0.75
Current application of sentinel lymph node lymphoscintigraphy to detect various cancer metastases. Hell J Nucl Med (2006) 0.75
[Assessement of the usefulness of whole body scintigraphy after administration of 6 MBq of 131I in the diagnostic of breast cancer]. Przegl Lek (2011) 0.75
[Serum levels of 25(OH)D3 in patients with prostate cancer compared to healthy men]. Przegl Lek (2013) 0.75
Neuroendocrine neoplasms of the small intestine and appendix - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol (2017) 0.75
Clinical and scintigraphic (99mTc-MIBI SPECT) heart evaluation in young acutely carbon monoxide poisoned patients. Przegl Lek (2003) 0.75
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms in Krakow and Krakow district in 2007-2011. Endokrynol Pol (2017) 0.75
Colorectal neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol (2017) 0.75
Radioimmunotherapy in follicular lymphomas, a retrospective analysis of the Polish Lymphoma Research Group's (PLRG) experience. Nucl Med Rev Cent East Eur (2007) 0.75
(99m)Tc-EDDA/HYNIC-octreotate - a new radiotracer for detection and staging of NET: a case of metastatic duodenal carcinoid. Nucl Med Rev Cent East Eur (2005) 0.75
[Alcohol consumption and the risk of insulin resistance--population based study]. Przegl Lek (2007) 0.75
Radioimmunotherapy for lymphoma - analysis of clinical trials and treatment algorithms. Nucl Med Rev Cent East Eur (2007) 0.75
[Current opinions on pathogenesis, diagnostic procedures and management of gastric neuroendocrine tumors]. Przegl Lek (2009) 0.75
Pancreatic neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol (2013) 0.75
[Symptoms and early diagnostic possibilities of pancreatic endocrine cells hyperplasia (nesidioblastosis)]. Przegl Lek (2012) 0.75
Gastroduodenal neuroendocrine neoplasms, including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol (2017) 0.75